Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ)
CNY 8.61
(1.41%)
CNY 8.61
(1.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 507.61 Million CNY | 59.75% |
| 2022 | 317.75 Million CNY | 54.29% |
| 2021 | 205.94 Million CNY | 98.2% |
| 2020 | 103.9 Million CNY | 13.75% |
| 2019 | 91.34 Million CNY | 23.08% |
| 2018 | 74.21 Million CNY | 25.38% |
| 2017 | 59.19 Million CNY | -12.73% |
| 2016 | 67.82 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 552.69 Million CNY | 8.88% |
| 2024 Q2 | 528.78 Million CNY | -1.33% |
| 2023 Q4 | 507.61 Million CNY | -3.67% |
| 2023 Q1 | 262.16 Million CNY | -17.5% |
| 2023 Q2 | 286.16 Million CNY | 9.16% |
| 2023 Q3 | 526.95 Million CNY | 84.15% |
| 2023 FY | 507.61 Million CNY | 59.75% |
| 2022 Q1 | 264.9 Million CNY | 28.63% |
| 2022 FY | 317.75 Million CNY | 54.29% |
| 2022 Q4 | 317.75 Million CNY | 40.61% |
| 2022 Q3 | 225.97 Million CNY | -9.86% |
| 2022 Q2 | 250.7 Million CNY | -5.36% |
| 2021 FY | 205.94 Million CNY | 98.2% |
| 2021 Q4 | 205.94 Million CNY | 0.01% |
| 2021 Q3 | 205.9 Million CNY | -6.08% |
| 2021 Q2 | 219.23 Million CNY | 16.9% |
| 2021 Q1 | 187.54 Million CNY | 80.5% |
| 2020 FY | 103.9 Million CNY | 13.75% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 103.9 Million CNY | -14.86% |
| 2020 Q2 | 130.03 Million CNY | 0.0% |
| 2020 Q3 | 122.04 Million CNY | -6.15% |
| 2019 FY | 91.34 Million CNY | 23.08% |
| 2019 Q4 | 91.34 Million CNY | 0.0% |
| 2019 Q1 | 75.38 Million CNY | 0.0% |
| 2018 FY | 74.21 Million CNY | 25.38% |
| 2017 FY | 59.19 Million CNY | -12.73% |
| 2016 FY | 67.82 Million CNY | 0.0% |